Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Goodrx Holdings Inc Cl A (NQ: GDRX )

6.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.970
Bid (Size) 6.700 (1)
Ask (Size) 7.050 (7)
Prev. Close 6.970
Today's Range 6.970 - 6.970
52wk Range 4.135 - 9.370
Shares Outstanding 412,429,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GoodRx Announces Date for 2024 Investor Day
From GoodRx Holdings, Inc.
Via Business Wire
GOODRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against GoodRx Holdings, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+24.02%
+24.02%
1 Month
-1.41%
-1.41%
3 Month
+4.19%
+4.19%
6 Month
+26.73%
+26.73%
1 Year
+23.14%
+23.14%

More News

Read More
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Why GoodRx Surged Today
Via The Motley Fool
The Latest Analyst Ratings For GoodRx Holdings
Via Benzinga
GOODRX HOLDINGS, INC. (NASDAQ: GDRX) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against GoodRx Holdings, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
GDRX Alert: Rosen, Skilled Investor Counsel, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GDRX
From The Rosen Law Firm, P.A.
Via Business Wire
GDRX INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc. And Encourages Investors With Losses To Contact The Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Earnings Scheduled For February 29, 2024
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For GoodRx Holdings
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
GoodRx Announces Date for First Quarter 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
Via Benzinga
Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
GoodRx Interim CEO Extends Commitment to Company
From GoodRx Holdings, Inc.
Via Business Wire
These Analysts Increase Their Forecasts On GoodRx Following Q4 Earnings
Via Benzinga
Why GoodRx Stock Soared Today
Via The Motley Fool
GoodRx (GDRX) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Is Telemedicine Firm GoodRx's Shares Surging Today
Via Benzinga
GoodRx Reports Fourth Quarter and Full Year 2023 Results
From GoodRx Holdings, Inc.
Via Business Wire
This healthcare stock making a buzz with 160% growth
Via MarketBeat
Topics Economy
Exposures Economy
GoodRx to Participate in Upcoming Investor Conferences
From GoodRx Holdings, Inc.
Via Business Wire
Gene therapy: Why does it cost millions for a single treatment?
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.